J Joseph Melenhorst
Overview
Explore the profile of J Joseph Melenhorst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
7006
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oliveira B, Bari S, Melenhorst J
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941752
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough in the treatment of relapsed and refractory B-cell malignancies, such as chronic lymphocytic leukemia (CLL), inducing long-term, sometimes curative, responses....
2.
Gregoire C, Melenhorst J
Nat Cancer
. 2024 Dec;
5(12):1768-1770.
PMID: 39690224
No abstract available.
3.
Feng B, Bai Z, Zhou X, Zhao Y, Xie Y, Huang X, et al.
Nature
. 2024 Sep;
634(8034):712-720.
PMID: 39322665
Current cancer immunotherapy predominately focuses on eliciting type 1 immune responses fighting cancer; however, long-term complete remission remains uncommon. A pivotal question arises as to whether type 2 immunity can...
4.
Bai Z, Feng B, McClory S, de Oliveira B, Diorio C, Gregoire C, et al.
Nature
. 2024 Sep;
634(8034):702-711.
PMID: 39322664
Despite a high response rate in chimeric antigen receptor (CAR) T cell therapy for acute lymphocytic leukaemia (ALL), approximately 50% of patients relapse within the first year, representing an urgent...
5.
van Bruggen J, Peters F, Mes M, Rietveld J, Cerretani E, Cretenet G, et al.
Blood Adv
. 2024 Jul;
8(17):4633-4646.
PMID: 39042920
Autologous T-cell-based therapies, such as chimeric antigen receptor (CAR) T-cell therapy, exhibit low success rates in chronic lymphocytic leukemia (CLL) and correlate with a dysfunctional T-cell phenotype observed in patients....
6.
Melenhorst J, Oliveira B
J Immunother Cancer
. 2024 Mar;
12(3).
PMID: 38485191
No abstract available.
7.
Haas A, Golden R, Litzky L, Engels B, Zhao L, Xu F, et al.
Mol Ther
. 2023 Jun;
31(8):2309-2325.
PMID: 37312454
Multiple clinical studies have treated mesothelin (MSLN)-positive solid tumors by administering MSLN-directed chimeric antigen receptor (CAR) T cells. Although these products are generally safe, efficacy is limited. Therefore, we generated...
8.
Collins M, Jung I, Zhao Z, Apodaca K, Kong W, Lundh S, et al.
Cancer Res Commun
. 2023 Mar;
2(9):1089-1103.
PMID: 36922932
Significance: CLL cells insufficiently activate CAR T cells, driven by low levels of costimulatory molecules on the tumor. LN-derived CLL cells are more costimulatory and mediate enhanced CAR T-cell killing....
9.
Melenhorst J, Chen G, Wang M, Porter D, Chen C, Collins M, et al.
Nature
. 2022 Dec;
612(7941):E22.
PMID: 36477542
No abstract available.
10.
Dhodapkar K, Cohen A, Kaushal A, Garfall A, Manalo R, Carr A, et al.
Blood Cancer Discov
. 2022 Aug;
3(6):490-501.
PMID: 36026513
Significance: There is an unmet need to identify determinants of durable responses following BCMA CAR T therapy of myeloma. High-dimensional analysis of the TME was performed to identify features of...